216 related articles for article (PubMed ID: 21882181)
1. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Kim JJ; Vaziri SA; Rini BI; Elson P; Garcia JA; Wirka R; Dreicer R; Ganapathi MK; Ganapathi R
Cancer; 2012 Apr; 118(7):1946-54. PubMed ID: 21882181
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.
Eechoute K; van der Veldt AA; Oosting S; Kappers MH; Wessels JA; Gelderblom H; Guchelaar HJ; Reyners AK; van Herpen CM; Haanen JB; Mathijssen RH; Boven E
Clin Pharmacol Ther; 2012 Oct; 92(4):503-10. PubMed ID: 22948895
[TBL] [Abstract][Full Text] [Related]
3. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Cohen DP; Lu DR; Chen I; Hariharan S; Gore ME; Figlin RA; Baum MS; Motzer RJ
J Natl Cancer Inst; 2011 May; 103(9):763-73. PubMed ID: 21527770
[TBL] [Abstract][Full Text] [Related]
4. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
[TBL] [Abstract][Full Text] [Related]
5. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
Scartozzi M; Bianconi M; Faloppi L; Loretelli C; Bittoni A; Del Prete M; Giampieri R; Maccaroni E; Nicoletti S; Burattini L; Minardi D; Muzzonigro G; Montironi R; Cascinu S
Br J Cancer; 2013 Mar; 108(5):1126-32. PubMed ID: 23511629
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
Dornbusch J; Walter M; Gottschalk A; Obaje A; Junker K; Ohlmann CH; Meinhardt M; Zacharis A; Zastrow S; Schoffer O; Grimm MO; Klug SJ; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1171-82. PubMed ID: 26935927
[TBL] [Abstract][Full Text] [Related]
7. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
George S; Reichardt P; Lechner T; Li S; Cohen DP; Demetri GD
Ann Oncol; 2012 Dec; 23(12):3180-3187. PubMed ID: 22858558
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
[TBL] [Abstract][Full Text] [Related]
9. Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
Bilen MA; Zurita AJ; Ilias-Khan NA; Chen HC; Wang X; Kearney AY; Hodges S; Jonasch E; Huang S; Khakoo AY; Tannir NM
Oncologist; 2015 Oct; 20(10):1140-8. PubMed ID: 26306901
[TBL] [Abstract][Full Text] [Related]
10. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.
Stewart GD; O'Mahony FC; Laird A; Rashid S; Martin SA; Eory L; Lubbock AL; Nanda J; O'Donnell M; Mackay A; Mullen P; McNeill SA; Riddick AC; Aitchison M; Berney D; Bex A; Overton IM; Harrison DJ; Powles T
Eur Urol; 2014 Nov; 66(5):956-63. PubMed ID: 24821582
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
Diekstra MH; Belaustegui A; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; García-Donas J; Rodríguez-Antona C; Rini BI; Guchelaar HJ
Pharmacogenomics J; 2017 Jan; 17(1):42-46. PubMed ID: 26810136
[TBL] [Abstract][Full Text] [Related]
12. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
Motzer RJ; Hutson TE; Hudes GR; Figlin RA; Martini JF; English PA; Huang X; Valota O; Williams JA
Cancer Chemother Pharmacol; 2014 Oct; 74(4):739-50. PubMed ID: 25100134
[TBL] [Abstract][Full Text] [Related]
13. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
[TBL] [Abstract][Full Text] [Related]
14. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
[TBL] [Abstract][Full Text] [Related]
15. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954
[TBL] [Abstract][Full Text] [Related]
16. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.
Diekstra MH; Liu X; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur J Clin Pharmacol; 2015 Dec; 71(12):1477-84. PubMed ID: 26387812
[TBL] [Abstract][Full Text] [Related]
17. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Bostad L; Edelmann RJ; Akslen LA; Beisland C; Straume O
J Pathol Clin Res; 2018 Apr; 4(2):114-123. PubMed ID: 29665322
[TBL] [Abstract][Full Text] [Related]
18. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B; Lambrechts D; Van Brussel T; Wolter P; Cardinaels N; Joniau S; Lerut E; Karadimou A; Couchy G; Sebe P; Ravaud A; Zerbib M; Caty A; Paridaens R; Schöffski P; Verkarre V; Berger J; Patard JJ; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Oct; 53(10):1413-22. PubMed ID: 24874929
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
20. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
Beuselinck B; Verbiest A; Couchy G; Job S; de Reynies A; Meiller C; Albersen M; Verkarre V; Lerut E; Méjean A; Patard JJ; Laguerre B; Rioux-Leclercq N; Schöffski P; Oudard S; Zucman-Rossi J
Acta Oncol; 2018 Apr; 57(4):498-508. PubMed ID: 29095068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]